

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/173731 A1

(51) International Patent Classification:

A61K 31/325 (2006.01) C07C 271/02 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2021/019490

(22) International Filing Date:

24 February 2021 (24.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/981,516 25 February 2020 (25.02.2020) US

(71) Applicant: UNIVERSITY OF TENNESSEE
RESEARCH FOUNDATION [US/US]; UT Conference

Center, Suite 211, 600 Henley Street, Knoxville, Tennessee
37996 (US).

(72) Inventors: NARAYANAN, Ramesh; 5426 Courtney Avenue,
Tuscaloosa, Alabama 35406 (US). PONNUSAMY,
Thamarai; KRICT Division of Drug Discovery Research,
141 Gajeongro Yuseong-gu, Daejeon, Daejeon 34114 (KR).
MILLER, Duane D.; 1646 Forsythe Trail, Collierville,
Tennessee 38017 (US). HE, Yali; 2072 Duntreath Meadows,
Germantown, New York 38139 (US). HWANG,
Dong-Jin; 5162 Jon Oak Drive, Arlington, Tennessee
38002 (US).

(74) Agent: COHEN, Mark S. et al.; Pearl Cohen Zedek Latzer
Baratz LLP, Times Square Tower, 7 Times Square, New
York, New York 10036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

(54) Title: SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAS) AND METHODS OF USE THERE-
OF




Figure 1

(57) Abstract: This invention relates to selective androgen receptor covalent antagonists, synthetic intermediates and by-products, and related compounds, and compositions comprising the same, and uses thereof in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR.

[Continued on next page]



WO 2021/173731 A1

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))